GCIA
VOR icon

Gabelli & Co Investment Advisers’s Vor Biopharma VOR Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,039
Closed -$14.9K – 279
2025
Q1 		$14.9K Sell
1,039
-461
-31% -$11.1K ﹤0.01% 225
2024
Q4 		$33.3K Buy
+1,500
New +$24.9K 0.01% 213

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Gabelli & Co Investment Advisers's VOR Position: Q2 2025 in Review

Gabelli & Co Investment Advisers sold out of Vor Biopharma (VOR) in Q2 2025, closing a stake of 1,039 shares — an estimated $14.9K sold.

Gabelli & Co Investment Advisers first reported a position in VOR in Q4 2024 and held it in 2 quarters. The position peaked at $33.3K in Q4 2024. 35 funds tracked by Wall St. Rank hold VOR as of Q2 2025.

  • Gabelli & Co Investment Advisers reported no remaining Vor Biopharma position as of Q2 2025 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 1,039 Vor Biopharma shares in Q2 2025, an estimated $14.9K.
  • Gabelli & Co Investment Advisers first reported a position in Vor Biopharma in Q4 2024 and held it in 2 quarters.
  • Gabelli & Co Investment Advisers's Vor Biopharma position peaked at $33.3K in Q4 2024.
  • 35 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2025.

Based on Gabelli & Co Investment Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.